KBP Biosciences Announces Completion of Enrollment to its Phase 3 CLARION-CKD Study of Ocedurenone for Uncontrolled Hypertension in Patients with Advanced Chronic Kidney Disease (CKD)

The pharmacology experimental platform allows KBP to identify and progress those
products with significant differentiation.
KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs.
Our integrated discovery and development platform enables us to efficiently bring new drugs from bench to clinics around the world.
View recent and past KBP stories,
including press releases and media coverages.